Errant Gene Therapeutics, LLC ("EGT"), a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center ("MSKCC"). TNS 9.55.3 developed by EGT pursuant to an exclusive license agreement with Sloan Kettering Institute (SKI), will be used for MSKCC's upcoming beta Thalassemia human clinical trial...
More...
More...